TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Optimal Timing for US for Early Diagnosis and Risk Stratification of VOD/SOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score of Delis-Kaplan Executive Function System (D-KEFS) Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Score of Word Interference Test (CWIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Score of Symbol Digit Modalities (SDMT)- Oral Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concordance rate between molecular response and radiologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of drug related dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (CR/PR/SD) according to RECIST criteria 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of objective response (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinic and functional outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child screen time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parent health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak Plasma Concentration (Cmax) of Remimazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Remimazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of M01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of M01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flu Vaccine Take-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Fibromyalgia Impact Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in glycemic control (hemoglobin A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Glomerular Filtration Rate (GFR) of Greater Than 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Eye Dryness Symptom (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in feelings of social isolation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in sense of meaning and purpose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-Reported Symptoms After Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change Self-Reported Quality of Life After Treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biologic effect on inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Qualitative report of any adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of responders as measured by the Hamilton Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cell death in primary infant leukemia samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of vaginal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: rate of low-grade perineal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: feasibility of alloreactive CD56+/CD3- donor NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of alloreactive CD56+/CD3- donor NK cells
Endpoint domain: Adverse events/effects
Primary endpoint: Polyphenol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cancellation due to low ovarian response
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sensory Organization Test (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bioequivalence between formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rapid control of haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced mortality post-haemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Infarct size corrected for area at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in total AIMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral breast tumor recurrence (IBTR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of falls recorded
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle thickness of lumbar multifidus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cross-sectional area of lumbar multifidus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pennation angle of lumbar multifidus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of liver-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory Test Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ambulatory Blood Pressure (ABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fasted Blood Sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerated Eltrombopag Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean subjective SL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baby development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HB at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC(0-36h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of NDV-3 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of anal incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death from all causes at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Maximum concentration in plasma following last dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration in plasma following last dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve over the last dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days required to attainment of full feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of enrolled patients for whom a personalized vaccine is developed and ready to administer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of enrolled patients who receive at least 1 dose of vaccine at any time post-enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical diagnosis of irritable bowel syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cigarettes smoked in the home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Growth of microbial organisms
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes of hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Autism spectrum symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm thickness and thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lack of CIED Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Pregnancy Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: GVHD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to GVHD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of acute abdomen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of acute abdomen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum COMP Accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emotional manifestation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen disturbance index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lowest oxygen saturation (Lsat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Margins With False Positive Device Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: low birth weight
Endpoint domain: Mortality/survival
Primary endpoint: sudden infant death syndrome (SIDS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in the 7.5 Meter Shuttle Run Test for GMFCS Level III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Social Wellbeing Domain of the KINDL-R Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent Reduction in EASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Vaginal dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacodynamics (biomarkers of drug effect)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dim light melatonin onset (DLMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serotonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNA transcripts correlating with disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased Economic Vulnerability
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Increased Collective Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Decreased Sexually Transmitted Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total HIV-DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: location of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Informed Consent Part A (QuIC-A) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal knee extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Exercise Self-Efficacy Scale (ESES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to reach TOF ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Preoperative low back pain and radicular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decision to have surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Ischemia Driven Target Lesion Failure (ID-TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Controlled Disease According to Investigator Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Global objective tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in health related quality of life lymphedema
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood sugar area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of the VibraTip® device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Area Under Curve (AUC) of Cefazolin plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum inhibitory concentration (MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7 Day Point Prevalence of Cigarette Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin and hematocrit concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence and numbers of blood transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline in hepatorenal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Psoriasis Activity and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite healing measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Radial Artery Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delivered-dose of platinum 24 hours after IV injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of AP5346
Endpoint domain: Adverse events/effects
Primary endpoint: Haemodynamic parameters measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Summed Ocular Inflammation Score (SOIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin Incrementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of subjects who completely lost index ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Daily Normalized Daytime Average Number of Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Treatment-free remission after imatinib discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HbA1c [Millimoles/Mole (mmol/Mol)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative reduction in circulating osteoprotegerin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciprofloxacin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relief of Overall IBS Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relief of Abdominal Pain/Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: L-Arginine availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta Forced Expiratory Volume in 1 second (FEV1%) predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Use of sun protection
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in ImPACT Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Donor Derived Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Demonstrating Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % morphology match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of ganglion cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Location of ganglion cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BOLD Response on fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in c-peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration-time profile in stomach and small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve of mortality prediction scores
Endpoint domain: Mortality/survival
Primary endpoint: Choline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Citrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of hypotensive events
Endpoint domain: Adverse events/effects
Primary endpoint: Organ-failure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute toxicities of the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Electromyogram and Electroneurophysiologic test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score on Global Outcomes Assessment of Laparoscopic Skills
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of antiviral prophylaxis
Endpoint domain: Resource use
Primary endpoint: Blood Pressure Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with qualified tumor biopsy specimen at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Voluntary Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Down's Attention Memory and Executive Function Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Part I of the Adaptive Behaviour Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients achieving a VLE image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post prandial capillary blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: antiphospholipid (APL) antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Liver status improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of medication consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RNA Biomarkers from Needle Muscle Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI brain volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in density of Pseudomonas aeruginosa in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Six-minute-walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrement of the pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes